Hillevax, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
HLVX
Hillevax, INCHilleVax reports significantly reduced net losses in Q2 2025, driven by cost cuts and the discontinuation of its lead vaccine candidate, as it moves towards acquisition by XOMA.
HLVX
Hillevax, INC10-Q: HilleVax Reports Q1 2025 Financial Results; Cites Reduced R&D Spending After HIL-214 Discontinuation
HilleVax, Inc. reports a significantly reduced net loss for Q1 2025 compared to Q1 2024, primarily due to decreased research and development expenses following the discontinuation of HIL-214 development in infants.
HLVX
Hillevax, INCHilleVax discontinues development of its lead vaccine candidate, HIL-214, after a Phase 2b trial failed to meet its primary endpoint, and announces workforce reductions.
HLVX
Hillevax, INCHilleVax's Phase 2b trial for its norovirus vaccine candidate, HIL-214, failed to meet its primary endpoint, leading to a workforce reduction and strategic shift.
HLVX
Hillevax, INCHilleVax reported a net loss of $46.8 million for the first quarter of 2024, while advancing its norovirus vaccine candidate, HIL-214, and acquiring rights to a new vaccine candidate, HIL-216.